Sign in or Register

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Renal Cell Cancer

Fig.1 Renal cell carcinoma

Renal cell carcinoma (RCC) is a kind of kidney cancer that starts from the lining of the proximal convoluted tubule, which is a kind of the very small tubes in the kidney and is responsible for transporting primary urine. RCC is the overwhelming type of kidney cancer in adults, accounting for approximately 90–95% of cases. The body is particularly good at hiding the symptoms and as a result people with RCC often have advanced disease by the time it is diagnosed. The initial symptoms of RCC often include: flank pain (40%), fever (20%), weight loss (33%), blood in the urine (occurring in about 40% of affected persons at the time they first seek medical assistance), a mass in the flank or abdomen (25%), high blood pressure (20%), night sweats and feeling unwell. Some potential prognostic markers, like Lactate dehydrogenase A in clear cell, have been studied recently.